TORONTO, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Maricann Group Inc. (CSE:MARI)(FRANKFURT: 75M)(OTCQB:MRRCF)(“Maricann”
or the “Company) is excited to announce the official launch of MariPlant, the Company’s European nutraceutical line of business.
MariPlant products will be available for sale in Germany through www.mariplant.de beginning on August 20, 2018, with strategic expansion planned throughout the
European Union. Maricann’s first product launch is a soft gel formulation loaded with 25mg of CBD that utilizes the
multi-patented VESIsorb® delivery system to ensure optimum absorption and bioavailability.
“Maricann is pleased to bring a superior CBD product to the German marketplace. This development symbolizes a significant move
to strengthen our global leadership position as we introduce the first of many patented formulations that utilize VESIsorb,” Stated
Ben Ward, CEO.
Maricann’s product launch represents many first-to-market milestones in the German cannabis industry, including the first:
- VESIsorb® formulation specifically adapted for cannabinoids;
- Standardized CBD product with measured and proven stability data; and
- Formulation with a strategic CBD:BCP (beta-caryophyllene) ratio of 4:1
In 2017, through a commercialization agreement with SourceOne Global Partners, Maricann acquired the supply rights to VESIsorb®
for use with cannabis for human consumption in Canada, Germany, and other territories.
Multiple clinical studies have demonstrated the absorption and bioavailability benefits of VESIsorb®, a science-backed drug
delivery technology with a robust portfolio of international patents. VESIsorb® has now been successfully adapted to optimize the
performance of cannabis formulations in the human body. Since 2007, close to 200 million consumers in all six continents have
safely and effectively used a natural product formulated with VESIsorb®.
According to Jesse Lopez, CEO and founder of SourceOne Global Partners, Maricann’s commitment to building an immediate
infrastructure for German market leadership has pioneered a new standard for cannabis products in Europe. “Maricann has all of the
critical elements to champion the VESIsorb® drug delivery system in the emerging global cannabis industry. With a focus on
innovation and clinical research, they also have the financial strength to build awareness and educate consumers on these superior
product applications,” Lopez said.
About Maricann Group Inc.
Maricann is a vertically integrated producer and distributor of cannabis for medical purposes. The company was
founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario
where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from
the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland.
Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq.
m) facility and will continue to pursue new opportunities in Europe.
Forward Looking Statements
This news release includes forward-looking information and statements, which may include, but are not limited
to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other
plans, intentions, expectations, estimates, and beliefs of the Company. Forward-looking information and statements involve and are
subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results,
performance, or achievements of the Company to be materially different from future events, results, performance, and achievements
expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking
information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties
inherent in such information and statements, there can be no assurance that any such forward-looking information and statements
will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and
should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and
statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and
disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that
actual events or results could or do differ from those projected in any forward looking information and statements herein, whether
as a result of new information, future events or results, or otherwise, except as required by applicable laws.
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news
release.
For more information about Maricann, please visit our website at www.maricann.com
CONTACT INFORMATION
Investor Relations
Graham Farrell
Director of Investor Relations
graham@maricann.com
647-643-7665
Corporate Headquarters (Canada)
Maricann Group Inc. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada
289-288-6274
European Headquarters (Germany)
Maricann GmbH
Thierschstrasse 3, 80538 Munchen, Deutschland
